<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03243851</url>
  </required_header>
  <id_info>
    <org_study_id>KNOG-1501</org_study_id>
    <nct_id>NCT03243851</nct_id>
  </id_info>
  <brief_title>Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma</brief_title>
  <acronym>METT</acronym>
  <official_title>Efficacy and Safety of Low Dose Temozolomide Plus Metformin as Combination Chemotherapy Compared With Low Dose Temozolomide Plus Placebo in Patient With Recurrent or Refractory Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong-Kil Hong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin&#xD;
      as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with&#xD;
      recurrent or refractory Glioblastoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or&#xD;
      placebo for the patients with recurrent or refractory Glioblastoma.&#xD;
&#xD;
      The dosage of the Metformin will follow the domestically permitted dose to minimize side&#xD;
      effects.&#xD;
&#xD;
      The patients will be allocated randomly to arm 1(experimental) and arm 2(placebo controlled)&#xD;
      and administered the investigational products for up to 6 cycle. Each cycle consists of 4&#xD;
      weeks.&#xD;
&#xD;
      After 6 cycle(24 weeks), the patients will be checked progression and survival every 24 weeks&#xD;
      up to 96 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1 : Low dose temozolomide+metformin Arm 2 : Low dose temozolomide+placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of progression-free survival obtained from progression-free survival curve</measure>
    <time_frame>24 weeks</time_frame>
    <description>Comparison of progression-free survival obtained from progression-free survival curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks thereafter every 24 weeks up to 96 weeks</time_frame>
    <description>Tumor Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control probability</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks thereafter every 24 weeks up to 96 weeks</time_frame>
    <description>Tumor control probability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month progression free survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>6 month progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month overall survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>6 month overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the quality of life of cancer patients</measure>
    <time_frame>4 weeks, 8 weeks, 16 weeks, 24 weeks</time_frame>
    <description>EORTC QLQ-C30 and EORTC QLQ-BN20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide :&#xD;
1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks&#xD;
Metformin :&#xD;
1st cycle (4 weeks)&#xD;
1 week(1st~7th day) = 1,000mg/day&#xD;
1 week(8th~14th day) = 1,500mg/day&#xD;
2 weeks(15th ~28th day) = 2,000mg/day&#xD;
2nd to 6th cycle (20 weeks) = 2,000mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Temozolomide :&#xD;
1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks&#xD;
Placebo:&#xD;
1st cycle (4 weeks)&#xD;
1 week(1st~7th day) = 1,000mg/day&#xD;
1 week(8th~14th day) = 1,500mg/day&#xD;
2 weeks(15th~28th day) = 2,000mg/day&#xD;
2nd to 6th cycle (20 weeks) = 2,000mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide+Metformin</intervention_name>
    <description>Low dose temozolomide+metformin for 24 weeks</description>
    <arm_group_label>Temozolomide+metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide+Placebo</intervention_name>
    <description>Low dose temozolomide+placebo for 24 weeks</description>
    <arm_group_label>Temozolomide+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Progressive or recurrent Glioblastoma conformed by histopathological or radiological&#xD;
             diagnosis. Progressive or recurrent Glioblastoma during or after standard therapy&#xD;
             (Temozolomide after Temozolomide and radiation therapy; Stupp regimen) after&#xD;
             histopathological diagnosis of Glioblastoma Recurrence or progression is diagnosed&#xD;
             according to histopathological diagnosis or revised RANO(Response Assessment in&#xD;
             Neuro-Oncology) criteria c&#xD;
&#xD;
          2. Karnofsky performance status(KPS) ≥ 60%&#xD;
&#xD;
          3. Age ≥ 19 years old&#xD;
&#xD;
          4. At least 4 weeks after operation or chemotherapy&#xD;
&#xD;
          5. Normal in hematological finding, liver and kidney function&#xD;
&#xD;
               -  Hematology ANC &gt; 1.500/mm³, Platelet &gt; 100,000/mm³, WBC &gt; 3×10^9/L, Hemoglobin &gt;&#xD;
                  9g/dL&#xD;
&#xD;
               -  Liver function Total Bilirubin level ≤ 1.5×ULN(in case of isolated&#xD;
                  hyperbilirubinemia ≤2.5 x ULN) AST / ALT &lt; 2.5×ULN&#xD;
&#xD;
               -  Renal function Serum creatinine ≤ 1.5mg/dL&#xD;
&#xD;
          6. Be informed of the nature of the study and obtained a written informed consent&#xD;
&#xD;
          7. A legal representative agrees to the trial when a subject is unable to communicate&#xD;
             smoothly due to neurologic defect&#xD;
&#xD;
          8. If a fertile woman who has been confirmed negative to a urine or blood pregnancy test&#xD;
             within 28 days prior to the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast feeding&#xD;
&#xD;
          2. Cancer history within 5 years excluding cancer in the skin cells and cervix&#xD;
&#xD;
          3. Active infections within two weeks&#xD;
&#xD;
          4. Leptomeningeal metastasis&#xD;
&#xD;
          5. Patients diagnosed with diabetes&#xD;
&#xD;
          6. Hypersensitive or intolerance to Metformin&#xD;
&#xD;
          7. Patients who are currently taking Metformin, sulfonylureas, thiazolidinediones, and&#xD;
             insulin, regardless of reason&#xD;
&#xD;
          8. Other serious diseases or medical conditions that include :&#xD;
&#xD;
               -  Patients who suffer from unstable heart disease despite treatment.&#xD;
&#xD;
               -  Patients having a heart attack within 6 months prior to the start of trial&#xD;
&#xD;
               -  Patients who suffer from severe nerve or psychosis that includes dementia or&#xD;
                  strokes.&#xD;
&#xD;
               -  Patients with an uncontrolled infection&#xD;
&#xD;
               -  Patient with uncontrolled hypertension, congestive heart failure, unstable&#xD;
                  angina, or incomplete arrhythmia&#xD;
&#xD;
          9. Those who have participated in other clinical trials may not recover from the toxicity&#xD;
             of the treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Kil Hong, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Ilsan</city>
        <state>Gyeonggi-Do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-Do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-Do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-Do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hospital, Korea</name>
      <address>
        <city>Suwon-si</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Yong-Kil Hong</investigator_full_name>
    <investigator_title>MD., PhD.</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

